Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (1...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of neuropsychopharmacology 2003-12, Vol.6 (4), p.325-337, Article S1461145703003651
Main Authors: Kasper, Siegfried, Lerman, Mark N., McQuade, Robert D., Saha, Anutosh, Carson, William H., Ali, Mirza, Archibald, Donald, Ingenito, Gary, Marcus, Ronald, Pigott, Teresa
Format: Article
Language:English
Subjects:
Acute Disease
Adult
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Aripiprazole
Double-Blind Method
Female
Haloperidol - adverse effects
Haloperidol - therapeutic use
Humans
Long-Term Care
Male
Neurologic Examination - drug effects
Piperazines - adverse effects
Piperazines - therapeutic use
Psychiatric Status Rating Scales
Quinolones - adverse effects
Quinolones - therapeutic use
Recurrence
Schizophrenia - diagnosis
Schizophrenia - drug therapy
Schizophrenic Psychology
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. Aripiprazole demonstrated long-term efficacy that was comparable or superior to haloperidol across all symptoms measures, including significantly greater improvements for PANSS negative subscale scores and MADRS total score (p
ISSN:1461-1457
1469-5111
DOI:10.1017/S1461145703003651